{
    "clinical_study": {
        "@rank": "107814", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Confirm the efficacy demonstrated in a pilot study using high dose\n      cyclophosphamide in patients with severe aplastic anemia.\n\n      II.  Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide\n      shortens the time to recovery in these patients.\n\n      III.  Determine whether this regimen is efficacious in treating paroxysmal nocturnal\n      hemoglobinuria."
        }, 
        "brief_title": "Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria", 
        "condition": [
            "Aplastic Anemia", 
            "Paroxysmal Hemoglobinuria, Nocturnal"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic", 
                "Hemoglobinuria", 
                "Hemoglobinuria, Paroxysmal"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients receive high dose cyclophosphamide IV on days 1-4.  Beginning on\n      day 10, patients receive filgrastim (G-CSF) until the absolute neutrophil count is greater\n      than 1,000/mm3 for 2 consecutive days.\n\n      Patients are followed every 3 months for at least 2 years and annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Acquired severe aplastic anemia or paroxysmal nocturnal\n        hemoglobinuria Not a candidate for allogeneic bone marrow transplantation Must meet one of\n        the following criteria: - Severe aplastic anemia Less than 25% bone marrow cellularity and\n        depression in two of three blood counts (reticulocytes less than 40,000/mm3, platelet\n        count less than 20,000/mm3 and granulocytes less than 500/mm3) - Life-threatening\n        paroxysmal nocturnal hemoglobinuria Absolute neutrophil count less than 500/mm3, platelet\n        transfusion dependent, or thrombotic disease No Fanconi anemia No abnormal cytogenetics\n        --Patient Characteristics-- Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular:\n        Cardiac ejection fraction at least 45% Other: Not preterminal or moribund Not pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "25", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004464", 
            "org_study_id": "199/13895", 
            "secondary_id": [
                "JHOC-96011702", 
                "JHOC-9611"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "filgrastim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Lenograstim"
            ]
        }, 
        "keyword": [
            "aplastic anemia", 
            "hematologic disorders", 
            "paroxysmal nocturnal hemoglobinuria", 
            "rare disease"
        ], 
        "lastchanged_date": "March 28, 2007", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21231"
                }, 
                "name": "Johns Hopkins Oncology Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Robert A. Brodsky", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004464"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1996", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2007"
    }, 
    "geocoordinates": {
        "Johns Hopkins Oncology Center": "39.29 -76.612"
    }
}